📢 Gate广场 #NERO发帖挑战# 秀观点赢大奖活动火热开启!
Gate NERO生态周来袭!发帖秀出NERO项目洞察和活动实用攻略,瓜分30,000NERO!
💰️ 15位优质发帖用户 * 2,000枚NERO每人
如何参与:
1️⃣ 调研NERO项目
对NERO的基本面、社区治理、发展目标、代币经济模型等方面进行研究,分享你对项目的深度研究。
2️⃣ 参与并分享真实体验
参与NERO生态周相关活动,并晒出你的参与截图、收益图或实用教程。可以是收益展示、简明易懂的新手攻略、小窍门,也可以是行情点位分析,内容详实优先。
3️⃣ 鼓励带新互动
如果你的帖子吸引到他人参与活动,或者有好友评论“已参与/已交易”,将大幅提升你的获奖概率!
NERO热门活动(帖文需附以下活动链接):
NERO Chain (NERO) 生态周:Gate 已上线 NERO 现货交易,为回馈平台用户,HODLer Airdrop、Launchpool、CandyDrop、余币宝已上线 NERO,邀您体验。参与攻略见公告:https://www.gate.com/announcements/article/46284
高质量帖子Tips:
教程越详细、图片越直观、互动量越高,获奖几率越大!
市场见解独到、真实参与经历、有带新互动者,评选将优先考虑。
帖子需原创,字数不少于250字,且需获得至少3条有效互动
BioSig commodity tokenization strategy
Key Points:* BioSig and Streamex merge to tokenize commodities on blockchain.
The initiative aims to introduce liquidity and transparency to the commodities market, impacting its $142 trillion value.
Funding and Institutional Backing in BioSig’s Commodity Shift
BioSig Technologies Inc., previously a medical technology company, has merged with Streamex to pivot towards blockchain tokenization of commodities. Led by CEO Henry McPhie, this endeavor includes securing up to $1.1 billion funding comprised of convertible bonds and equity facilities.
The merger seeks to integrate commodity trading onto blockchain platforms, notably enhancing liquidity and transparency. The initiative emphasizes gold-backed assets and targets a $142 trillion market landscape, marking a significant pivot for BioSig’s operations.
Blockchain Opportunity: BioSig Targets $142 Trillion Commodity Market
Did you know? BioSig’s move to tokenize commodities is reminiscent of earlier attempts like Pax Gold but is amplified by institutional backing and a $1.1 billion investment.
Solana (SOL) stands at $151.16 with a market cap of $80.96 billion, dominating 2.41% of the market. A trading volume of $3.77 billion reflects a 12.64% change. Over 90 days, Solana’s price rose by 41.89%, per CoinMarketCap data on July 8, 2025.
| | | --- | | DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing. |